Revolution Medicines, Inc. (RVMD) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.30B USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 218.77M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -1.63B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.30B | (m) | $218.77M | $-1.63B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.13B | (m) | $180.60M | $-1.39B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $987.33M | $0.00 | $118.39M | $-1.18B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $880.49M | (m) | $107.13M | $-1.04B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $769.15M | (m) | $97.13M | $-897.50M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $679.95M | (m) | $88.07M | $-789.42M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $592.23M | $0.00 | $79.20M | $-689.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $552.61M | $742.00K | $82.19M | $-653.20M | (m) | 74475.74% | 11076.15% | (m) | (m) |
| 2024-06-30 | $509.17M | $742.00K | $75.08M | $-600.73M | (m) | 68621.16% | 10118.06% | (m) | (m) |
| 2024-03-31 | $472.22M | $4.57M | $68.28M | $-552.89M | (m) | 10342.05% | 1495.42% | (m) | (m) |
| 2023-12-31 | $423.14M | $11.58M | $61.77M | $-487.19M | (m) | 3654.09% | 533.44% | (m) | (m) |
| 2023-09-30 | $340.79M | $26.17M | $44.66M | $-368.91M | (m) | 1302.32% | 170.67% | (m) | (m) |
| 2023-06-30 | $302.51M | $29.52M | $39.13M | $-322.19M | (m) | 1024.62% | 132.55% | (m) | (m) |
| 2023-03-31 | $265.53M | $34.82M | $34.25M | $-275.49M | (m) | 762.67% | 98.38% | (m) | (m) |
| 2022-12-31 | $253.07M | $35.38M | $31.20M | $-258.28M | $0.00 | 715.30% | 88.17% | (m) | Reported |
| 2022-09-30 | $240.63M | $29.51M | $29.08M | $-249.49M | $0.00 | 815.41% | 98.53% | (m) | Reported |
| 2022-06-30 | $217.65M | $27.25M | $26.77M | $-226.12M | $0.00 | 798.55% | 98.21% | (m) | Reported |
| 2022-03-31 | $202.58M | $26.84M | $23.98M | $-208.56M | $0.00 | 754.85% | 89.36% | (m) | Reported |
| 2021-12-31 | $186.95M | $29.39M | $20.72M | $-188.01M | $12.00K | 636.09% | 70.51% | -15667.33× | Reported |
| 2021-09-30 | $170.27M | $28.68M | $17.16M | $-169.18M | $26.00K | 593.68% | 59.83% | -6506.73× | Reported |
| 2021-06-30 | $158.67M | $40.24M | $14.00M | $-143.56M | $43.00K | 394.30% | 34.80% | -3338.67× | Reported |
| 2021-03-31 | $145.65M | $41.57M | $10.71M | $-127.01M | $62.00K | 350.40% | 25.76% | -2048.58× | Reported |
| 2020-12-31 | $132.25M | $42.98M | $8.89M | $-110.70M | $71.00K | 307.68% | 20.67% | -1559.11× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $91.75M | $50.04M | $3.16M | $-54.12M | $106.00K | 183.36% | 6.32% | -510.57× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $51.08M | $20.16M | $855.00K | $-40.33M | $116.00K | 253.33% | 4.24% | -347.66× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |